What is AUTOLUS THERAPEUTICS PLC's earnings per share (EPS)?

AUTOLUS THERAPEUTICS PLC (AUTL) reported diluted earnings per share of $-1.08 for fiscal year 2025. This represents a -25.6% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

AUTOLUS THERAPEUTICS PLC Financials

AUTL

Source SEC Filings (10-K/10-Q) Updated Mar 27, 2026 Currency USD FYE March

This page shows AUTOLUS THERAPEUTICS PLC (AUTL) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Financial Profile 42/100

Based on FY2025 annual data. Scores normalized against common benchmarks. How we calculate these scores

Profitability

AUTOLUS THERAPEUTICS PLC has an operating margin of -364.0%, meaning the company retains $-364 of operating profit per $100 of revenue. This below-average margin results in a low score of 0/100, suggesting thin profitability after operating expenses. This is up from -2385.6% the prior year.

Growth

100

AUTOLUS THERAPEUTICS PLC's revenue surged 634.4% year-over-year to $74.3M, reflecting rapid business expansion. This strong growth earns a score of 100/100.

Leverage

AUTOLUS THERAPEUTICS PLC has a moderate D/E ratio of 2.31. This balance of debt and equity financing earns a leverage score of 55/100.

Liquidity

100

With a current ratio of 5.94, AUTOLUS THERAPEUTICS PLC holds $5.94 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 100/100.

Cash Flow

While AUTOLUS THERAPEUTICS PLC generated -$283.6M in operating cash flow, capex of $19.0M consumed most of it, leaving -$302.6M in free cash flow. This results in a low score of 0/100, reflecting heavy capital investment rather than weak cash generation.

Returns

AUTOLUS THERAPEUTICS PLC generates a -161.4% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100. This is down from -51.6% the prior year.

Piotroski F-Score Weak

2/9

AUTOLUS THERAPEUTICS PLC passes 2 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), 1 of 2 efficiency signals pass.

Earnings Quality Low Quality

0.99x

For every $1 of reported earnings, AUTOLUS THERAPEUTICS PLC generates $0.99 in operating cash flow (-$283.6M OCF vs -$287.5M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Interest Coverage At Risk

-7.4x

AUTOLUS THERAPEUTICS PLC earns $-7.4 in operating income for every $1 of interest expense (-$270.5M vs $36.7M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$74.3M

YoY+634.4%

AUTOLUS THERAPEUTICS PLC generated $74.3M in revenue in fiscal year 2025. This represents an increase of 634.4% from the prior year.

EBITDA

-$262.2M

YoY-12.1%

AUTOLUS THERAPEUTICS PLC's EBITDA was -$262.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 12.1% from the prior year.

Net Income

-$287.5M

YoY-30.3%

AUTOLUS THERAPEUTICS PLC reported -$287.5M in net income in fiscal year 2025. This represents a decrease of 30.3% from the prior year.

EPS (Diluted)

$-1.08

YoY-25.6%

AUTOLUS THERAPEUTICS PLC earned $-1.08 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 25.6% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$302.6M

YoY-32.5%

AUTOLUS THERAPEUTICS PLC generated -$302.6M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 32.5% from the prior year.

Cash & Debt

$104.1M

YoY-54.2%

5Y CAGR-7.5%

AUTOLUS THERAPEUTICS PLC held $104.1M in cash against $0 in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

266M

5Y CAGR+38.4%

AUTOLUS THERAPEUTICS PLC had 266M shares outstanding in fiscal year 2025.

Margins & Returns

Gross Margin

-29.7%

YoY-17.2pp

AUTOLUS THERAPEUTICS PLC's gross margin was -29.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 17.2 percentage points from the prior year.

Operating Margin

-364.0%

YoY+2021.6pp

AUTOLUS THERAPEUTICS PLC's operating margin was -364.0% in fiscal year 2025, reflecting core business profitability. This is up 2021.6 percentage points from the prior year.

Net Margin

-386.9%

YoY+1793.6pp

AUTOLUS THERAPEUTICS PLC's net profit margin was -386.9% in fiscal year 2025, showing the share of revenue converted to profit. This is up 1793.6 percentage points from the prior year.

Return on Equity

-161.4%

YoY-109.8pp

5Y CAGR-93.8pp

AUTOLUS THERAPEUTICS PLC's ROE was -161.4% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 109.8 percentage points from the prior year.

Capital Allocation

R&D Spending

$117.7M

YoY-15.0%

5Y CAGR-2.7%

AUTOLUS THERAPEUTICS PLC invested $117.7M in research and development in fiscal year 2025. This represents a decrease of 15.0% from the prior year.

Share Buybacks

N/A

Capital Expenditures

$19.0M

YoY-13.7%

5Y CAGR+5.3%

AUTOLUS THERAPEUTICS PLC invested $19.0M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 13.7% from the prior year.

AUTL Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$74.3M+634.4%	$10.1M+496.0%	$1.7M	N/A	N/A	N/A
Cost of Revenue	$96.4M+746.3%	$11.4M	$0	N/A	N/A	N/A
Gross Profit	-$22.1M-1640.4%	-$1.3M-174.6%	$1.7M	N/A	N/A	N/A
R&D Expenses	$117.7M-15.0%	$138.4M+6.1%	$130.5M+11.2%	$117.4M+5.9%	$110.8M-17.8%	$134.9M
SG&A Expenses	$131.9M+30.5%	$101.1M+116.2%	$46.7M+46.5%	$31.9M+0.1%	$31.9M-8.9%	$35.0M
Operating Income	-$270.5M-12.1%	-$241.4M-34.3%	-$179.7M-25.3%	-$143.4M-1.7%	-$141.1M+16.1%	-$168.1M
Interest Expense	$36.7M+294.6%	$9.3M-79.4%	$45.1M+406.1%	$8.9M+705.9%	$1.1M	$0
Income Tax	$2.0M+29.1%	$1.5M+8142.1%	-$19K-107.0%	$272K+369.0%	$58K+100.2%	-$24.2M
Net Income	-$287.5M-30.3%	-$220.7M-5.9%	-$208.4M-40.0%	-$148.8M-4.7%	-$142.1M0.0%	-$142.1M
EPS (Diluted)	$-1.08-25.6%	$-0.86+28.3%	$-1.20+23.6%	$-1.57+20.3%	$-1.97+28.6%	$-2.76

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Revenue	$21.2M+1.3%	$20.9M+132.9%	$9.0M	N/A	$0	$0-100.0%	$10.1M	N/A
Cost of Revenue	$28.6M+17.2%	$24.4M+36.2%	$18.0M	N/A	$0	$0	$0	N/A
Gross Profit	-$7.4M-111.5%	-$3.5M+60.7%	-$9.0M	N/A	$0	$0-100.0%	$10.1M	N/A
R&D Expenses	$27.9M+1.7%	$27.4M+2.6%	$26.7M	N/A	$40.3M+10.1%	$36.6M+19.4%	$30.7M	N/A
SG&A Expenses	$36.3M+19.9%	$30.3M+2.5%	$29.5M	N/A	$27.3M+24.8%	$21.9M+20.5%	$18.2M	N/A
Operating Income	-$71.6M-17.0%	-$61.2M+6.2%	-$65.2M	N/A	-$67.9M-15.2%	-$58.9M-52.0%	-$38.8M	N/A
Interest Expense	$10.5M+254.0%	-$6.8M-167.3%	$10.1M	N/A	$10.7M+5.0%	$10.2M-47.2%	$19.3M	N/A
Income Tax	$532K+34.0%	$397K-82.2%	$2.2M	N/A	$22K-56.9%	$51K+737.5%	-$8K	N/A
Net Income	-$79.1M-65.1%	-$47.9M+31.7%	-$70.2M	N/A	-$82.1M-40.9%	-$58.3M-10.6%	-$52.7M	N/A
EPS (Diluted)	$-0.30-66.7%	$-0.18+30.8%	$-0.26	N/A	$-0.31-40.9%	$-0.22+8.3%	$-0.24	N/A

AUTL Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$589.1M-24.7%	$782.7M+108.5%	$375.4M-23.4%	$490.3M+20.9%	$405.6M+37.8%	$294.2M
Current Assets	$435.9M-34.0%	$660.9M+140.1%	$275.3M-35.3%	$425.8M+22.7%	$347.0M+76.1%	$197.0M
Cash & Equivalents	$104.1M-54.2%	$227.4M-5.1%	$239.6M-37.4%	$382.4M+23.2%	$310.3M+101.4%	$154.1M
Inventory	$33.2M+702.5%	$4.1M	$0	N/A	N/A	N/A
Accounts Receivable	$24.0M+160060.0%	$15K-86.2%	$109K-9.9%	$121K	$0	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$410.9M+15.6%	$355.4M+34.7%	$263.9M+37.7%	$191.6M+107.7%	$92.2M+9.5%	$84.2M
Current Liabilities	$73.4M+20.9%	$60.7M+35.8%	$44.7M-3.5%	$46.4M+62.4%	$28.6M-15.1%	$33.6M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$178.1M-58.3%	$427.3M+283.3%	$111.5M-62.7%	$298.7M-4.7%	$313.3M+49.2%	$210.0M
Retained Earnings	-$1.4B-26.2%	-$1.1B-25.1%	-$878.6M-31.1%	-$670.2M-28.5%	-$521.3M-37.5%	-$379.2M

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Total Assets	$661.9M-8.2%	$721.0M-3.4%	$746.3M-4.6%	$782.7M-5.4%	$827.5M-3.1%	$853.6M-5.3%	$901.4M+140.1%	$375.4M
Current Assets	$514.6M-10.4%	$574.3M-6.7%	$615.8M-6.8%	$660.9M-8.0%	$718.1M-5.3%	$758.6M-5.7%	$804.3M+192.2%	$275.3M
Cash & Equivalents	$86.1M-30.4%	$123.8M+29.3%	$95.8M-57.9%	$227.4M-65.4%	$657.1M-6.9%	$705.9M-6.9%	$758.5M+216.6%	$239.6M
Inventory	$27.7M+15.8%	$23.9M+63.5%	$14.6M+254.0%	$4.1M	N/A	N/A	N/A	$0
Accounts Receivable	N/A	N/A	N/A	$15K	$0	$0	$0-100.0%	$109K
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$396.5M+5.9%	$374.5M-0.2%	$375.2M+5.6%	$355.4M+1.4%	$350.5M+7.6%	$325.8M+2.0%	$319.4M+21.0%	$263.9M
Current Liabilities	$83.1M+21.9%	$68.2M+2.3%	$66.6M+9.7%	$60.7M+15.8%	$52.5M+28.3%	$40.9M-7.0%	$44.0M-1.7%	$44.7M
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Equity	$265.5M-23.4%	$346.5M-6.6%	$371.1M-13.2%	$427.3M-10.4%	$477.0M-9.6%	$527.8M-9.3%	$582.0M+422.1%	$111.5M
Retained Earnings	-$1.3B-6.5%	-$1.2B-4.1%	-$1.2B-6.4%	-$1.1B-2.6%	-$1.1B-8.3%	-$989.5M-6.3%	-$931.3M-6.0%	-$878.6M

AUTL Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	-$283.6M-37.5%	-$206.3M-41.7%	-$145.6M-29.6%	-$112.3M+4.7%	-$117.9M-0.1%	-$117.8M
Capital Expenditures	$19.0M-13.7%	$22.1M+100.9%	$11.0M+1.3%	$10.8M+22.4%	$8.9M-39.7%	$14.7M
Free Cash Flow	-$302.6M-32.5%	-$228.3M-45.8%	-$156.6M-27.1%	-$123.1M+2.8%	-$126.7M+4.3%	-$132.4M
Investing Cash Flow	$158.5M+140.2%	-$394.6M-3491.4%	-$11.0M-1.3%	-$10.8M-22.4%	-$8.9M+39.7%	-$14.7M
Financing Cash Flow	-$4.3M-100.7%	$589.6M+66867.2%	-$883K-100.4%	$223.6M-21.3%	$284.1M+281.7%	$74.4M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Operating Cash Flow	-$67.9M+6.7%	-$72.8M+3.7%	-$75.6M-99.2%	-$37.9M+50.6%	-$76.7M-50.2%	-$51.1M-26.1%	-$40.5M-63.1%	-$24.8M
Capital Expenditures	$4.4M-39.4%	$7.3M-11.7%	$8.2M-25.8%	$11.1M+15.9%	$9.6M+1040.2%	$841K+57.8%	$533K-63.9%	$1.5M
Free Cash Flow	-$72.3M+9.7%	-$80.1M+4.5%	-$83.8M-70.9%	-$49.0M+43.2%	-$86.3M-66.3%	-$51.9M-26.5%	-$41.0M-56.0%	-$26.3M
Investing Cash Flow	$35.5M-62.9%	$95.9M+261.1%	-$59.5M+84.5%	-$383.6M-3900.3%	-$9.6M-1040.2%	-$841K-57.8%	-$533K+63.9%	-$1.5M
Financing Cash Flow	-$1.8M-131.0%	-$768K	$0-100.0%	$30.0M+16120.0%	$185K+108.9%	-$2.1M-100.4%	$561.4M+2440947.8%	$23K
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

AUTL Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	-29.7%-17.2pp	-12.5%-112.5pp	100.0%	N/A	N/A	N/A
Operating Margin	-364.0%+2021.6pp	-2385.6%+8197.5pp	-10583.1%	N/A	N/A	N/A
Net Margin	-386.9%+1793.6pp	-2180.5%+10091.8pp	-12272.3%	N/A	N/A	N/A
Return on Equity	-161.4%-109.8pp	-51.6%+135.3pp	-186.9%-137.1pp	-49.8%-4.5pp	-45.4%+22.3pp	-67.7%
Return on Assets	-48.8%-20.6pp	-28.2%+27.3pp	-55.5%-25.2pp	-30.4%+4.7pp	-35.0%+13.3pp	-48.3%
Current Ratio	5.94-4.9	10.88+4.7	6.15-3.0	9.18-3.0	12.15+6.3	5.86
Debt-to-Equity	2.31+1.5	0.83-1.5	2.37+1.7	0.64+0.3	0.29-0.1	0.40
FCF Margin	-407.2%+1849.2pp	-2256.4%+6964.6pp	-9221.0%	N/A	N/A	N/A

Metric	Q2'26	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24
Gross Margin	-35.1%-18.3pp	-16.8%+83.0pp	-99.9%	N/A	N/A	N/A	100.0%	N/A
Operating Margin	-337.9%-45.4pp	-292.6%+433.8pp	-726.3%	N/A	N/A	N/A	-384.1%	N/A
Net Margin	-373.3%-144.3pp	-229.0%+552.1pp	-781.1%	N/A	N/A	N/A	-522.1%	N/A
Return on Equity	-29.8%-16.0pp	-13.8%+5.1pp	-18.9%	N/A	-17.2%-6.2pp	-11.0%-2.0pp	-9.0%	N/A
Return on Assets	-11.9%-5.3pp	-6.7%+2.7pp	-9.4%	N/A	-9.9%-3.1pp	-6.8%-1.0pp	-5.9%	N/A
Current Ratio	6.19-2.2	8.43-0.8	9.24-1.6	10.88-2.8	13.69-4.9	18.55+0.3	18.29+12.1	6.15
Debt-to-Equity	1.49+0.4	1.08+0.1	1.01+0.2	0.83+0.1	0.73+0.1	0.62+0.1	0.55-1.8	2.37
FCF Margin	-341.2%+41.5pp	-382.6%+550.4pp	-933.1%	N/A	N/A	N/A	-406.8%	N/A

Similar Companies

Adc Therapeutics Sa ADCT

$462.4M

Cullinan Oncology Inc CGEM

$812.3M

Y-Mabs Therapeutics YMAB

$391.2M

Benitec Biopharm BNTC

$344.6M

Aura Biosciences, Inc. AURA

$394.2M

Frequently Asked Questions

What is AUTOLUS THERAPEUTICS PLC's annual revenue?

AUTOLUS THERAPEUTICS PLC (AUTL) reported $74.3M in total revenue for fiscal year 2025. This represents a 634.4% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is AUTOLUS THERAPEUTICS PLC's revenue growing?

AUTOLUS THERAPEUTICS PLC (AUTL) revenue grew by 634.4% year-over-year, from $10.1M to $74.3M in fiscal year 2025.

Is AUTOLUS THERAPEUTICS PLC profitable?

No, AUTOLUS THERAPEUTICS PLC (AUTL) reported a net income of -$287.5M in fiscal year 2025, with a net profit margin of -386.9%.

What is AUTOLUS THERAPEUTICS PLC's EBITDA?

AUTOLUS THERAPEUTICS PLC (AUTL) had EBITDA of -$262.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is AUTOLUS THERAPEUTICS PLC's gross margin?

AUTOLUS THERAPEUTICS PLC (AUTL) had a gross margin of -29.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is AUTOLUS THERAPEUTICS PLC's operating margin?

AUTOLUS THERAPEUTICS PLC (AUTL) had an operating margin of -364.0% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is AUTOLUS THERAPEUTICS PLC's net profit margin?

AUTOLUS THERAPEUTICS PLC (AUTL) had a net profit margin of -386.9% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is AUTOLUS THERAPEUTICS PLC's return on equity (ROE)?

AUTOLUS THERAPEUTICS PLC (AUTL) has a return on equity of -161.4% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is AUTOLUS THERAPEUTICS PLC's free cash flow?

AUTOLUS THERAPEUTICS PLC (AUTL) generated -$302.6M in free cash flow during fiscal year 2025. This represents a -32.5% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is AUTOLUS THERAPEUTICS PLC's operating cash flow?

AUTOLUS THERAPEUTICS PLC (AUTL) generated -$283.6M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are AUTOLUS THERAPEUTICS PLC's total assets?

AUTOLUS THERAPEUTICS PLC (AUTL) had $589.1M in total assets as of fiscal year 2025, including both current and long-term assets.

What are AUTOLUS THERAPEUTICS PLC's capital expenditures?

AUTOLUS THERAPEUTICS PLC (AUTL) invested $19.0M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does AUTOLUS THERAPEUTICS PLC spend on research and development?

AUTOLUS THERAPEUTICS PLC (AUTL) invested $117.7M in research and development during fiscal year 2025.

How many shares does AUTOLUS THERAPEUTICS PLC have outstanding?

AUTOLUS THERAPEUTICS PLC (AUTL) had 266M shares outstanding as of fiscal year 2025.

What is AUTOLUS THERAPEUTICS PLC's current ratio?

AUTOLUS THERAPEUTICS PLC (AUTL) had a current ratio of 5.94 as of fiscal year 2025, which is generally considered healthy.

What is AUTOLUS THERAPEUTICS PLC's debt-to-equity ratio?

AUTOLUS THERAPEUTICS PLC (AUTL) had a debt-to-equity ratio of 2.31 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is AUTOLUS THERAPEUTICS PLC's return on assets (ROA)?

AUTOLUS THERAPEUTICS PLC (AUTL) had a return on assets of -48.8% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is AUTOLUS THERAPEUTICS PLC's cash runway?

Based on fiscal year 2025 data, AUTOLUS THERAPEUTICS PLC (AUTL) had $104.1M in cash against an annual operating cash burn of $283.6M. This gives an estimated cash runway of approximately 4 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is AUTOLUS THERAPEUTICS PLC's Piotroski F-Score?

AUTOLUS THERAPEUTICS PLC (AUTL) has a Piotroski F-Score of 2 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are AUTOLUS THERAPEUTICS PLC's earnings high quality?

AUTOLUS THERAPEUTICS PLC (AUTL) has an earnings quality ratio of 0.99x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can AUTOLUS THERAPEUTICS PLC cover its interest payments?

AUTOLUS THERAPEUTICS PLC (AUTL) has an interest coverage ratio of -7.4x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is AUTOLUS THERAPEUTICS PLC?

AUTOLUS THERAPEUTICS PLC (AUTL) scores 42 out of 100 on our Financial Profile, indicating moderate overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.